Abstract
Solasodine rhamnosyl glycosides (SRGs) induce apoptosis in a wide variety of cancer
cells and are more effective than many well-established anticancer agents. Combination
therapy of SRGs with cisplatin treats cisplatin–resistant cells such as lung cancer
and breast cancer cells. Anticancer therapies with SRGs have been used intravenously,
intraperitoneally, intralesionally, orally, and topically. Data is now presented that
in addition to apoptosis and, perhaps as a consequence thereof, SRGs also have an
effect of stimulating lasting immunity against cancer as shown with a mouse model
and the terminal cancer Sarcoma 180. Mice were inoculated i. p. with Sarcoma 180.
Groups of animals were administered SRGs half an hour after Sarcoma 180 inoculation.
Mice treated with Sarcoma 180 but not with SRGs all died within 20 days. Four doses
of SRGs caused total remission of Sarcoma 180 activity. Mice that went into remission
were then reinoculated 20 days later with the cancer. Ten of twelve SRGs cured-animals
were resistant to reinduction of terminal doses of the cancer. In comparison, twelve
of twelve mice treated with SRGs without initial Sarcoma 180 activity but which were
inoculated with Sarcoma 180 cells 20 days later, all died. In addition to apoptosis,
SRGs stimulate lasting immunity against cancer. SRGs could play an important role
in clinical management of diseases such a malignancy and also be used as a preventative
therapy.
Key words
cancer -
Solanum sodomaeum
- Solanaceae - solamargine - solasonine - apoptosis - immunity
References
1
Cham B E, Gilliver M, Wilson L.
Antitumour effects of glycoalkaloids isolated from Solanum sodomaeum L.
Planta Med.
1987;
53
34-36
2
Cham B E, Daunter B.
Solasodine glycosides. Selective cytoxicity for cancer cells and inhibition of cytotoxicity
by rhamnose in mice with sarcoma 180.
Cancer Lett.
1990;
55
221-225
3
Kuo K W, Hsu S H, Li Y P, Lin W L, Liu L F, Chang L C, Lin C C, Lin C N, Sheu H M.
Anticancer activity evaluation of the Solanum glycoalkaloid solamargine. Triggering apoptosis in human hepatoma cells.
Biochem Pharmacol.
2000;
60
1865-1873
4 Kuo K W, Lin C N. Pharmacological composition for treating cancer cells. United
States Patent 6,214,803 1999
5
Liang C H, Liu L F, Shiu L Y, Huang Y S, Chang L C, Kuo K W.
Action of solamargine on TNFs and cisplatin-resistant human lung cancer cells.
Biochem Biophys Res Commun.
2004;
322
751-758
6
Liang C H, Shiu L Y, Chang L C, Sheu H M, Kuo K W.
Solamargine upregulation of Fas, downregulation of HER 2, and enhancement of cytotoxicity
using epirubicin in NSCLC cells.
Mol Nutr Food Res.
2007;
51
999-1005
7
Millward M, Powell A, Daly P, Tyson S, Ferguson R, Carter S.
Results of phase I clinical trials of coramsine in patients with advanced solid tumors.
J Clin Oncol.
2006;
24
2070
8
Ono K, Kin S O, Han J.
Susceptibility of lysosomes to rupture is a determinant for plasma membrane disruption
in tumor necrosis factor alpha-induced cell death.
Mol Cell Biol.
2003;
23
665-676
9
Ono M, Nishimura K, Suzuki K, Fukushima T, Igoshi K, Yoshimitsu H, Ikeda T, Nohara T.
Steroidal glycosides from the underground parts of Solanum sodomaeum .
Chem Pharm Bull.
2006;
54
230-233
10
Cham B E.
Solasodine rhamnosyl glycosides specifically bind cancer cell receptors and induce
apoptosis and necrosis. Treatment for skin cancer and hope for internal cancers.
Res J Biol Sci.
2007;
2
503-514
11
Cham B E.
Solasodine rhamnosyl glycosides in a cream formulation is effective for treating large
and troublesome skin cancers.
Res J Biol Sci.
2007;
2
749-761
12
Cham B E.
Cancer intralesion chemotherapy with solasodine rhamnosyl glycosides.
Res J Biol Sci.
2008;
3
1008-1017
13
Shiu L Y, Chang L C, Liang C H, Huang Y S, Sheu H M, Kuo K W.
Solamargine induces apoptosis and sensitizes breast cancer cells to cisplatin.
Food Chem Toxicol.
2007;
45
2155-2164
14
Daunter B, Cham B E.
Solasodine glycosides. In vitro preferential cytotoxicity for human cancer cells.
Cancer Lett.
1990;
55
209-220
15
Li X, Zhao Y, Wu W K K, Liu S, Cui M, Lou H.
Solamargine induces apoptosis associated with p 53 transcription-dependent and transcription-independent
pathways in human osteosarcoma U20S cells.
Life Sci.
2011;
88
314-321
16
Cham B E.
Solasodine glycosides as anti-cancer agents: Pre-clinical and clinical studies.
Asia Pacif J Pharmacol.
1994;
9
113-118
17
Shiu L Y, Liang C H, Huang Y S, Sheu H M, Kuo K W.
Downregulation of HER2/neu receptor by solamargine enhances anticancer drug-mediated
cytotoxicity in breast cancer cells with high-expressing HER2/neu.
Cell Biol Toxicol.
2008;
24
1-10
18
Paquet C, Sané A T, Beauchemin M, Bertrand R.
Caspase-and mitochondrial dysfunction dependent mechanisms of lysosomal leakage and
cathepsin B activation in DNA damage-induced apoptosis.
Leukemia.
2005;
19
784-791
19
Sun L, Zhao Y, Yuan H, Li X, Cheng A, Lou H.
Solamargine, a steroidal alkaloid glycoside, induces oncosis in human K562 leukemia
and squamous cell carcinoma KB cells.
Cancer Chemother Pharmacol.
2010;
65
1125-1130
20
Chang L C, Tsai T R, Wang J J, Lin C N, Kuo K W.
The rhamnose moiety of solamargine plays a crucial role in triggering cell death by
apoptosis.
Biochem Biophys Res Commun.
1998;
242
21-25
21
Sun L, Zhao Y, Yuan H, Li X, Cheng A, Lou H.
Lysosomal-mitochondrial death pathway is induced by solamargine in human K562 leukemia
cells.
Toxicol In Vitro.
2010;
24
1504-1511
22
Cham B E, Wilson L.
HPLC of glycoalkaloids from Solanum sodomaeum .
Planta Med.
1987;
53
34-36
23
Lichtenstein A K, Kahle J, Bere J, Zigelboin J.
Successful immunotherapy with intraperitoneal Corynbacterium parvum in a murine ovarian cancer model is associated with the recruitment of tumor-lytic
neutrophils into the peritoneal cavity.
J Immunol.
1984;
133
519-526
24
Van der Most R G, Himbeck R, Aarens S, Carter S J, Larma I, Robinson C, Currice A,
Lake R A.
Antitumor efficacy of the novel chemotherapeutic agent coramsine is potentiated by
cotreatment with CpG-containing oligodeoxynucleotides.
J Immunother.
2006;
29
134-142
25
Cham B E, Vickery K, Tohidi-Esfahani R, Cossart Y.
Delipidation of a hepadnavirus: Viral inactivation and vaccine development.
J Virol Methods.
2006;
137
160-163
26
Cham B E, Daunter B, Evans R.
Topical treatment of malignant and premalignant skin cancers by very low concentrations
of a standard mixture of solasodine glycosides.
Cancer Lett.
1991;
59
183-192
27
Cham B E, Meares H M.
Glycoalkaloids from Solanum sodomaeum L. are effective in the treatment of skin cancers in man.
Cancer Lett.
1987;
36
111-118
28
Punjabi S, Cook L J, Kersey P, Marks R, Cerio R.
Solasodine glycoalkaloids: a novel topical therapy for basal cell carcinoma. A double-blind,
randomized, placebo-controlled, parallel group, multicentre study.
Int J Dermatol.
2008;
47
78-82
29
Cham B E.
Topical solasodine rhamnosyl glycosides derived from the eggplant treats large skin
cancers: two case reports.
Int J Clin Med.
2011;
2
473-477
30
Chataing B, Concepcion J L, Buitrago de Cristancho N, Usubillaga A.
Clinical study of the effectiveness of extracts alkaloids obtained of the fruits of
Solanum americanum Miller on Herpes simplex, Herpes to zoster and genital Herpes.
Rev Face Pharm Univ The Andes.
1996;
32
18-25
31
Thorne H V, Clarke G F, Skuce R.
The inactivation of herpes simplex virus by some Solanaceae glycoalkaloids.
Antivir Res.
1985;
5
335-343
Prof. Dr. Bill E. Cham
Australasian Medical Research
PO Box 7031
Port Vila
Republic of Vanuatu
South Pacific
Phone: +67 87 75 09 87
Email: bill.cham@gmail.com